Although the kidney protective effect of SGLT2 inhibitors in nondiabetic CKD patients had not been revealed until 2020 [22], the use of SGLT2 inhibitors had already been widespread in diabetic patients during the observation period (from 2014 to 2018). The gene discussed is SLC5A2; the disease is chronic kidney disease.